Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

3.3K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.1K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

1.5K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.5K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bilateral Cerebellar Hemispheric Ischemia in Cryptococcal Meningitis.

Cureus·2025
Same author

The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants.

Contemporary clinical trials·2025
Same author

Corneal confocal microscopy as a tool for detecting axonal degeneration in multiple sclerosis and correlation with severity: A meta-analysis.

Multiple sclerosis and related disorders·2025
Same author

"Do You Hear What I Hear?" Speech and Voice Alterations in Hearing Loss: A Systematic Review.

Journal of clinical medicine·2025
Same author

The bidirectional brain-cochlea axis: a scaffold for neurologic disease-associated hearing loss.

Brain communications·2024
Same author

Combining early lower eyelid surgery with neuromuscular retraining for synkinesis prevention after facial palsy: the role of the eye in aberrant facial nerve regeneration.

Frontiers in neurology·2024

Related Experiment Video

Updated: Mar 17, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Neurotherapeutic Strategies for Multiple Sclerosis.

Teresa C Frohman1, Shin C Beh2, Eric J Kildebeck3

  • 1Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA; Department of BioEngineering, University of Texas at Dallas, 800 West Campbell Road, Richardson, TX 75080, USA.

Neurologic Clinics
|July 23, 2016
PubMed
Summary

Multiple sclerosis (MS) is a common neurologic disease. This review covers 16 FDA-approved therapies and other treatments for MS, including options for pregnant individuals.

Keywords:
Adrenocorticotrophic hormoneCorticosteroidsDisease-modifying therapyExacerbationMSMultiple sclerosisPregnancy

More Related Videos

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.2K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

11.3K

Related Experiment Videos

Last Updated: Mar 17, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.2K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

11.3K

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple sclerosis (MS) is a leading cause of neurologic disability in young adults.
  • Current treatment landscape includes 16 FDA-approved disease-modifying therapies.
  • Additional agents are used for refractory MS cases.

Purpose of the Study:

  • To review US Food and Drug Administration (FDA)-approved therapies for multiple sclerosis (MS).
  • To discuss commonly used practice-based therapies for MS management.
  • To outline treatment considerations for pregnant individuals with MS.

Main Methods:

  • Literature review of FDA-approved medications for MS.
  • Analysis of clinical practice guidelines and expert consensus for MS treatment.
  • Examination of safety and efficacy data for MS therapies in pregnancy.

Main Results:

  • Sixteen disease-modifying therapies are currently FDA-approved for MS.
  • A range of conventional and alternative treatments are available.
  • Specific therapeutic strategies exist for managing MS during pregnancy.

Conclusions:

  • A comprehensive array of treatment options is available for MS patients.
  • Treatment decisions should be individualized based on disease activity and patient factors.
  • Management of MS in pregnant individuals requires careful consideration of risks and benefits.